The de-escalation of the biological disease-modifying anti-rheumatic drug (predominantly anti-TNF-α agents) the or the JAK inhibitor was not different from continuation of the initial regimen with respect to the incidence of serious infections (risk difference 0.01, 95% CI −0.00–0.02, p = 0.13, I2 = 0%). This evidence concerns the gene TNF and infection.